

REFERENCES

1. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. *Nephrol Dial Transplant*. 2017;32:1262.
2. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. *N Engl J Med*. 2008;359:1477.
3. Lanktree MB, Haghighi A, Guiard E, Iliuta IA, Song X, Harris PC, et al. Prevalence Estimates of polycystic kidney and liver disease by population sequencing. *J Am Soc Nephrol*. 2018;29:2593.
4. Cornec-Le Gall E, Audrezet MP, Le Meur Y, Chen JM, Ferec C. Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20 years on. *Hum Mut*. 2014;35:1393-406.
5. Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials. *J Am Soc Nephrol*. 2015;26:160.
6. Cornec-Le Gall E, Audrezet PP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol*. 2016;27:942-51.
7. Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, et al. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: Results from the TEMPO 3:4 Trial. *J Am Soc Nephrol*. 2017;28:1592.
8. Ars E, Bernis C, Fraga G, Furlano M, Martínez V, Martins J, et al. Documento de consenso de poliquistosis renal autosómica dominante. In: Grupo de trabajo de Enfermedades Renales Hereditarias de la Sociedad Española de Nefrología; July 2020, <http://dx.doi.org/10.1016/j.nefro.2021.05.009>.
9. Bae KT, Tao C, Zhu F, Bost JE, Chapman, Grantham JJ, et al. MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. *Clin J Am Soc Nephrol*. 2009;4:719.

Alba Rivas Oural*, Jose Joaquín Bande Fernández,
Luis Fernando Morán Fernández, Sheila Requena López,
Blanca Vivanco Allende, Elena Astudillo Cortés

Hospital Universitario Central de Asturias, Oviedo, Spain

*Corresponding author.

E-mail addresses: albarivasoural@gmail.com,
alba.rivas.oural@sergas.es (A. Rivas Oural).

2013-2514/© 2023 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).
<https://doi.org/10.1016/j.nefro.2023.01.001>

IgA nephropathy after long-term treatment with infliximab for Crohn's disease Crohn's disease, a review of two cases

Nefropatía IgA tras tratamiento prolongado con infliximab por enfermedad de Crohn, a propósito de dos casos

Dear Editor,

Tumor necrosis factor- α inhibitors (TNF- α inhibitors) are potent immunomodulators and have been associated with the development of autoimmunity, such as glomerulonephritis.^{1,2} Recently, investigators described a case of IgA nephropathy in patients with inflammatory bowel disease on a prolonged treatment with TNF- α inhibitors in sustained clinical remission of their intestinal disease, and with improvement after discontinuation of the drug, making the case less likely to be an extraintestinal manifestation.^{3,4}

In this regard we present two clinical cases from our hospital:

DOI of original article:
<https://doi.org/10.1016/j.nefro.2023.02.007>.

Case 1. The first case is a 20-year-old male, with Crohn's disease (CD) since 2013, who started treatment with infliximab and azathioprine, went into complete remission, and continued in monotherapy with infliximab since 2016. After seven years on treatment with infliximab (in April 2020), the patient suffered acute deterioration of renal function (Cr 1.8 mg/dL CKDEPI 51 mL/min /1.73 m²), nephrotic proteinuria (8 g/24 h) and microhematuria. A renal biopsy was performed with the finding of IgA nephropathy, M1 E0 S1 T0 in the Oxford classification (Fig. 1). Complete sustained remission of his CD was confirmed, infliximab was discontinued, and an angiotensin-II receptor antagonist was started at maximum tolerated doses and corticosteroids (prednisone 1 mg/kg/day for one month followed by a tapering regimen and discontinuation after six months). After 14 months, his CD relapsed, with no associated deterioration of renal function, and ustekinumab was started,






Fig. 1 – (A) Optical microscopic image showing glomerulus with mesangial proliferation at the expense of cellularity and matrix. (B) Immunofluorescence image with abundant and intense mesangial deposition for IgA (left) and C3 (right), this antibody also localized in Bowman's capsule of some glomeruli.

with a good response. After 18 months of renal biopsy, he had normal renal function (Cr 1.1 mg/dL CKDEPI 90 mL/min/1.73 m²), complete improvement of proteinuria (0.3 g/24 h) and no microhematuria.

Case 2. A 51-year-old woman with extensive Crohn's ileitis, stenosing, fistulous and with intra-abdominal abscess on debut in 2012, started treatment with azathioprine and infliximab in 2013 and have been in complete remission ever since. Azathioprine was discontinued in 2017 and infliximab monotherapy was maintained.

In March 2020, acute deterioration of renal function (Cr 1.6 mg/dL CKDEPI 36 mL/min /1.73 m²) together with proteinuria (0.4 g/24 h) and microhematuria was detected.

A renal biopsy was performed which confirmed the diagnosis of IgA nephropathy (M1 E0 S0 T1). Her CD remained in complete remission, infliximab was discontinued, and she received a course of corticosteroids (prednisone 1 mg/kg/day for one month and a tapering regimen with discontinuation of prednisone after six months). After 20 months she remains in complete remission of CD without specific treatment, with improvement in renal function (Cr 1.39 mg/dL CKDEPI 44 mL/min/1.73 m²), remission of proteinuria (0.2 g/24 h) and no microhematuria.

We present these two cases that support the relationship between the prolonged use of infliximab in patients with CD and the development of IgA nephropathy, also observed in other autoimmune pathologies such as rheumatoid arthritis, psoriasis and ankylosing spondylitis.^{1,2}

Although it is a rare complication, it is clinically important, as 25–30% of IgA nephropathy cases develop end-stage renal disease within 20–25 years of diagnosis, and in 10% of patients end-stage renal disease is achieved within five years of diagnosis. Early detection of this renal pathology allows early action to reverse or at least minimize kidney damage. In the case of secondary IgA nephropathy, the main treatment is to treat/eliminate the cause.⁵

As for the mechanism, it is postulated that the inhibition of TNF- α exerts a direct effect on lymphocyte function and cytokine production, changing the T-helper cytokine response from type 1 to type 2 secreting IL-4, IL-5 and IL-10, promoting humoral immunity, and inducing antibody production. These antibodies cross-react with aberrant IgA₁, which upon deposition in the mesangium leads to complement activation and the development of IgA nephropathy.¹

Therefore, it is of great importance to alert physicians using TNF- α inhibition to this possible adverse effect, and for them to perform routine analyses of renal function, proteinuria (in 24 h urine or in isolated urine with protein/creatinine ratio or albumin/creatinine ratio) and urine sediment. If there are alterations, they should refer patients to nephrology, as early diagnosis and treatment are essential for renal prognosis.

Funding

This work has not received any funding.

Conflict of interest

The authors declare that they have no conflicts of interest.

Acknowledgements

We thank the participants of the manuscript for their involvement and contribution to research in the field of nephrology.

REFERENCES

1. Chessa E, Piga M, Floris A, Congia M, Cangemi I, Mathieu A, et al. Biologics and targeted synthetic drugs can induce immune-mediated glomerular disorders in patients with rheumatic diseases: an updated systematic literature review. *BioDrugs*. 2021;1-12.
2. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. *Nephrol Dial Transplant*. 2005;20(7):1400-6.
3. Hokama Akira, Sonosaki T, Zamami R, Aoyama H, Kinjo T, Fujita J. Crohn disease complicated by IgA vasculitis during therapy with tumor necrosis factor- α inhibitor. *Pol Arch Intern Med*. 2019;129:283-4.

4. -Strobel T, Ahmed W, De la Sancha C, Bohm M, Fischer M. IgA nephropathy in the setting of Anti-TNF- α therapy for inflammatory bowel disease. *ACG Case Reports Journal*. 2020;7(9).
5. International Society of Nephrology. *Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis*. Chapter 2: Immunoglobulin A nephropathy (IgAN)/immunoglobulin A vasculitis (IgAV). *Kidney Int*. 2021;100:S1-276.

Silvia Sánchez Montero*, Elena Monfa Guix, Monica Sierra Ausín, Francisco Izquierdo García, Benjamin León Gómez, Catherine Vanesa Martinez-Rosero, Xhamy Yosue Martelli Guerrero, Erika Jenelia Romero Zaldumbide, Mario Alfredo Prieto Velasco, Cristina Lucas Alvarez, Aranzazu Sastre Lopez, George Estifan Kasabji

Nefrología, University Assistance Complex of Leon, León, Spain

*Corresponding author.

E-mail address: sisanchezm@mail.ucv.es (S.S. Montero).

2013-2514/© 2023 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). <https://doi.org/10.1016/j.nefro.2023.02.010>

Hodgkin lymphoma in a patient with kidney transplantation

Linfoma de Hodgkin en un paciente con trasplante renal

Dear Editor,

Malignancy is detected three times more in kidney transplant (KT) recipients than general population. Posttransplant lymphoproliferative disorders (PTLD) constitute nearly 20% of malignancies diagnosed after solid organ transplantations. Even though Hodgkin lymphomas (HL) formerly defined as Hodgkin Disease are less common lymphomas after transplantation compared to general population (HL accounts 13% and 7% of lymphomas in general population and posttransplant recipients respectively), relative risk for HL is 2.6 among posttransplant patients compared to the risk among kidney disease patients on waiting list. The incidence of HL after kidney transplantation was approximately reported as 0.1%.¹ The average age at diagnosis of posttransplant HL was found as 48.6 ± 11.9 years with male predominance (55% of the cases).

A 35-year-old male patient had a history of kidney transplantation due to chronic kidney failure with unknown etiology 11 years ago in another center. He had COVID-19 infection two years ago. In addition, he was diagnosed with cytomegalovirus (CMV) disease eight months ago during evaluation for acute elevation in serum creatinine levels to 3.3 mg/dL and treated via i.v. ganciclovir by then (Fig. 1). The doses of tacrolimus and mycophenolic acid were also decreased. Kidney biopsy revealed chronic allograft nephropathy (Fig. 2). While these infections the patient had night sweats, fever, and weight loss. Splenomegaly was discovered by abdominal ultrasonography coincidentally. While exploring severe anemia (hemoglobin level: 5.7 g/dL), multiple lymphadenopathies (LAP) approximately 3 cm in size were detected by computed tomography. The patient had been diagnosed with nodular sclerosis classic HL (NSCHL) as the laparoscopic excisional biopsy of paraaortic LAP resulted in

